Rheumatology
Advertisement
A study investigate physical activity characteristics in the non-pharmacologic management of lupus.
Dr. Mithu Maheswaranathan talks about the findings of a study which assessed obinutuzumab for patients with active lupus.
A recent study sought to better understand the clinical presentation, and prognosis of IgG4-related pachymeningitis.
Researchers sought to better address the gap in knowledge on acetaminophen safety in patients with osteoarthritis.
Bidirectional Mendelian randomization was used and a multi-trait analysis of GWAS was conducted.
The team will now carry out an analysis of already trialed treatments at this potential intervention point.
Dr. Mithu Maheswaranathan discusses the link between vitamin D levels and pregnancy outcomes in women with lupus.
A study sought to understand the use of herbal supplement treatment in adult patients with autoimmune skin diseases.
A study examined the phenotypic differences in patients with IgG4-RD with and without hypocomplementemia.
The US FDA approved the application for for equecabtagene autoleucel for the treatment of lupus.
The role of dietary and lifestyle interventions in the management of rheumatic disease is poorly understood.
Dr. Mithu Maheswaranathan on a study that shows metformin is a promising complementary therapy for SLE.
Patients with genetic risk factors with long-term exposure had a significantly higher risk of developing SLE.
A study found an independent relationship between hypertension and osteoporosis.
Treatment with ixekizumab led to rapid improvements in joint, skin, and nail symptoms for patients with psoriatic arthritis.
A study assessed glucocorticoid regimens on renal response, infections, and mortality in patients with lupus nephritis.
Systemic lupus erythematosus may be related to a greater risk of pregnancy complications.
A study assessed factors associated with kidney involvement in patients with systemic lupus erythematosus.
A study of real-world treatment and outcomes associated with ixekizumab found favorable efficacy in patients.
The FDA has approved Cyltezo, for the treatment of chronic inflammatory diseases.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.